Magnesium supplementation as an adjunct to fluoxetine therapy for depression
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: OBJECTIVES: To evaluate the effectiveness of magnesium supplementation as an adjunct to fluoxetine therapy for improving depressive symptoms and serum serotonin levels in patients with depression. METHODS: Consecutive patients aged 18 to 45 years who had been prescribed fluoxetine therapy for new-onset or chronic depression were recruited between November 2024 and February 2025 at the outpatient psychiatry clinic of Wahidin Sudirohusodo General Hospital and three affiliated hospitals in Makassar, Indonesia. Participants were randomised in an alternating sequence to receive either fluoxetine 20 mg/day alone or in combination with oral magnesium supplementation 250 mg/day. Outcomes were assessed at baseline and week 6. The severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale (HDRS). Blood samples were collected to measure serum serotonin levels. RESULTS: = 0.528, p < 0.001) after adjustment for baseline HDRS score and demographic covariates, indicating a large effect size. CONCLUSION: Magnesium supplementation as an adjunct to fluoxetine therapy improves HDRS total score in patients with depression.
DOI: 10.12809/eaap25122
Institution: Hasanuddin University
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7147532519
FWCI:
Cites:
Cited by:
Related to: